Saturday 17 October 2026 Export GELS’s income statement to Excel — free account

Gelteq Limited

GELS Healthcare Drug Manufacturers Specialty & Generic

Gelteq Limited’s revenue for fiscal 2025 (year ended June 2025) was $368,500.00, up 282.7% from fiscal 2024.

0.45 0.02 +4.65%

Follow GELS

Alert me

Market cap: $4.6M
P/E: —
Fwd P/E: —
Dividend yield: —
F-score: 4/9
Altman Z: 0.39
Beneish M: −0.73
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Older periods	Jun '24	Dec '24	Jun '25	Dec '25
ROE Full definition →	+2 more TTM periods Free account	—	—	0.00%	0.00%
ROA Full definition →		—	—	0.00%	0.00%
ROIC Full definition →		0.00%	0.00%	0.00%	0.00%
Return on Tangible Assets Full definition →		0.00%	0.00%	0.00%	0.00%
Average Days of Receivables Full definition →		0.00	0.00	0.00	0.00
Free Cash Flow per Share Full definition →		—	0.00	0.00	0.00
Free Cash Flow Full definition →		—	(4.26)	(6.63)	(6.83)
Capital Expenditures Full definition →		—	(0.03)	(0.01)	—
Other line items
Cash ROIC Full definition →		0.00%	(25.43%)	(50.24%)	(53.81%)
Accounts Receivable Turnover Full definition →		—	—	0.00	0.00
Accounts Payable Turnover Full definition →		—	—	0.00	0.00
Average Days of Payables Full definition →		0.00	0.00	0.00	0.00
Operating CF/Net income Full definition →		—	0.00	0.00	0.00
Depreciation/Fixed assets Full definition →		—	0.00	—	0.00
Capex/Depreciation Full definition →		—	0.00	0.00	—
Operating CF per Share Full definition →		—	0.00	0.00	0.00
Capex per Share Full definition →		—	0.00	0.00	—
Capex to Sales Full definition →		—	0.00	0.00	—

Show all line items

Columns are period end dates · fundamentals updated 5 Oct 2026